BioSpace News Archive

As part of a strategic restructuring, Proteostasis is laying off 13 members of its R&D workforce.

Dotmatics announced Version 5.2, a new release of the company’s informatics suite designed to enhance the end user experience and make scientists more productive.

New data for the immunotherapy DARZALEX (daratumumab) and first-in-class BTK inhibitor IMBRUVICA (ibrutinib) are among eight oral presentations from Janssen Research & Development, LLC, to be featured at the 59th American Society of Hematology Annual Meeting & Exhibition taking place December 9-12, in Atlanta, GA.

Net product revenue in the third quarter of 2017 achieved record levels.

Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.

Astra and its MedImmune division announced that two Phase III clinical trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.

Revenue for the three and nine months ended September 30, 2017 was $44.8 million and $85.4 million, compared to $20.8 million and $58.2 million for the three and nine months ended September 30, 2016, respectively.

This cash dividend will be distributed on Monday, November 20, to shareholders of record as of Monday, November 13, 2017.

The data presented at the 25th United European Gastroenterology Week (UEGW 2017) showed that patient-reported symptom improvement began as early as day 1 post ustekinumab IV infusion and was observed consistently at day 8 and beyond when compared with placebo.

Total sales in the third quarter of 2017 increased by 15.1% in both RMB terms and USD terms to $99.6 million from $86.5M in the same quarter of 2016.